ProQR Therapeutics N.V.

AI Score

0

Unlock

2.27
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
2.26
-0.44%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 2.13
Market Cap 234.27M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.31
PE Ratio (ttm) -7.32
Forward PE n/a
Analyst Buy
Ask 3
Volume 334,106
Avg. Volume (20D) 1,626,654
Open 2.30
Previous Close 2.27
Day's Range 2.19 - 2.34
52-Week Range 1.61 - 4.62
Beta undefined

About PRQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2014
Employees 156
Stock Exchange NASDAQ
Ticker Symbol PRQR

Analyst Forecast

According to 5 analyst ratings, the average rating for PRQR stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 252.42% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

ProQR Therapeutics N.V. is scheduled to release its earnings on Mar 12, 2025, before market opens.
Analysts project revenue of $6.97M, reflecting a 97.17% YoY growth and earnings per share of -0.15, making a 87.50% increase YoY.
2 months ago · Source
+5.6%
ProQR Therapeutics shares are trading higher afer ... Unlock content with Pro Subscription
5 months ago · Source
+12.57%
Pro QR Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.